miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 26, 2026

UPS (UPS) Q1 2025 Earnings Call Transcript

View original at nasdaq.com
UPS (UPS) Q1 2025 Earnings Call Transcript Image source: The Motley Fool. DATE Tuesday, April 29, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Carol TomeChief Financial Officer — Brian DykesPresident, U.S…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • UPS ultimate target is 400 facilities partially or fully automated with 200 facilities closed

    80% confidence
  • The world hasn't faced such enormous potential impacts to trade in more than 100 years

    80% confidence
  • UPS has built in chaos costs to manage volume and maintain service during Q2 facility closures, impacting margin improvement

    80% confidence
  • China-to-rest-of-world volume expected up 40% in Q2 2025

    80% confidence
  • International revenue expected down approximately 2% in Q2 2025

    80% confidence
  • U.S. Domestic operating margin expected up approximately 30 bps to approximately 9.3% in Q2 2025

    80% confidence
  • 95% of small package customers expect to maintain current shipping models despite tariffs

    80% confidence
  • U.S. ADV expected down approximately 9% in Q2 2025

    80% confidence
  • The only certainty is that UPS doesn't know which scenario will play out for full-year outlook

    80% confidence
  • Supply Chain Solutions revenue expected down approximately $500M in Q2 2025 due to Coyote divestiture

    80% confidence
  • Uncertainty surrounding global trade policies and other matters led to a drop in consumer confidence and muted demand in February-March 2025

    80% confidence
  • Many UPS SMB customers are 100% single-sourced from China, causing uncertainty due to 145% tariff announcement

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com